{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T05:38:44Z","timestamp":1789191524370,"version":"build-2803163510"},"reference-count":84,"publisher":"BMJ","issue":"3","license":[{"start":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T00:00:00Z","timestamp":1773878400000},"content-version":"unspecified","delay-in-days":18,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Canadian Institutes of Health Research (Foundation Scheme","award":["148443"],"award-info":[{"award-number":["148443"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2026,2,27]]},"published-print":{"date-parts":[[2026,3]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To evaluate the effectiveness of early administration of excitatory amino acid (EAA) inhibitors on long-term neurological outcomes in adults with acute moderate to severe traumatic brain injury (TBI).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>Systematic review and meta-analysis of randomised controlled trials (RCTs).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data sources<\/jats:title>\n                    <jats:p>MEDLINE, EMBASE, Cochrane CENTRAL, Web of Science, WHO International Clinical Trials Registry Platform and ClinicalTrials.gov from inception to January 2026.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Study selection<\/jats:title>\n                    <jats:p>RCTs comparing EAA inhibitors with placebo, standard care or any other interventions were included. Trials enrolled adult patients (\u226518 years) with moderate to severe TBI (Glasgow Coma Scale score \u226412) receiving the intervention within the acute phase of care (first week).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data extraction and synthesis<\/jats:title>\n                    <jats:p>Pairs of reviewers independently screened trials, extracted data, assessed the risk of bias (RoB) with the Cochrane RoB tool 2 and graded the certainty of evidence using the Grades of Recommendation, Assessment, Development and Evaluation approach. Random effects models were used for all effect measures and trial sequential analyses (TSA) were performed for each outcome.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Main outcome measures<\/jats:title>\n                    <jats:p>The primary outcome was long-term neurological function at 6\u2009months (or the nearest earlier time point), assessed with the Glasgow Outcome Scale (GOS) or extended version (GOS-E), using the classical definitions of an unfavourable outcome (GOS 1\u20133\u2009or GOS-E 1\u20134).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>28 trials enrolling 4238 patients were included. Early administration of EAA inhibitors was not associated with reduced unfavourable neurological outcomes (relative risk 0.93 (95% CI (0.84 to 1.03); I\u00b2=40%; 15 trials, n=3613, moderate certainty). No statistically significant difference was observed based on EAA inhibitor type, timing or duration of administration, RoB or TBI severity. Mortality, intensive care unit lengths of stay and mean intracranial pressure were not statistically different between groups, but hospital length of stay was reduced in the EAA inhibitors group. The early use of EAA inhibitors was not associated with adverse events (low certainty). TSA showed insufficient power for the primary outcome.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In adults with moderate to severe TBI, the early administration of EAA inhibitors was not associated with a reduction of unfavourable neurological outcomes. Further high-quality and adequately powered RCTs are required to clarify their role in TBI management.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>PROSPERO registration number<\/jats:title>\n                    <jats:p>CRD42025635527.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2025-108337","type":"journal-article","created":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T15:35:24Z","timestamp":1773934524000},"page":"e108337","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":2,"title":["Excitatory amino acid inhibitors in adults with acute moderate to severe traumatic brain injury: a systematic review and meta-analysis"],"prefix":"10.1136","volume":"16","author":[{"given":"Marwan","family":"Bouras","sequence":"first","affiliation":[{"name":"CHU de Qu\u00e9bec-Universit\u00e9 Laval Research Center, Population Health and Optimal Health Practice Research Unit (Trauma-Emergency-Critical Care Medicine), CHU de Qu\u00e9bec-Universit\u00e9 Laval, Qu\u00e9bec City, Qu\u00e9bec, Canada"},{"name":"Department of Anesthesiology and Critical Care Medicine, Brest University Hospital Centre, Brest, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Costerousse","sequence":"additional","affiliation":[{"name":"CHU de Qu\u00e9bec-Universit\u00e9 Laval Research Center, Population Health and Optimal Health Practice Research Unit (Trauma-Emergency-Critical Care Medicine), CHU de Qu\u00e9bec-Universit\u00e9 Laval, Qu\u00e9bec City, Qu\u00e9bec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3257-7878","authenticated-orcid":false,"given":"Michael","family":"Verret","sequence":"additional","affiliation":[{"name":"CHU de Qu\u00e9bec-Universit\u00e9 Laval Research Center, Population Health and Optimal Health Practice Research Unit (Trauma-Emergency-Critical Care Medicine), CHU de Qu\u00e9bec-Universit\u00e9 Laval, Qu\u00e9bec City, Qu\u00e9bec, Canada"},{"name":"Department of Anesthesiology and Critical Care Medicine, Universit\u00e9 Laval, Facult\u00e9 de M\u00e9decine, Qu\u00e9bec City, Qu\u00e9bec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"O\u2019connor","sequence":"additional","affiliation":[{"name":"CHU de Qu\u00e9bec-Universit\u00e9 Laval Research Center, Population Health and Optimal Health Practice Research Unit (Trauma-Emergency-Critical Care Medicine), CHU de Qu\u00e9bec-Universit\u00e9 Laval, Qu\u00e9bec City, Qu\u00e9bec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan","family":"Zarychanski","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Sections of Critical Care Medicine, of Hematology and of Medical Oncology, University of Manitoba, Winnipeg, Manitoba, Canada"},{"name":"Research Institute of Oncology and Hematology, CancerCare Manitoba, Winnipeg, Manitoba, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc-Aur\u00e8le","family":"Gagnon","sequence":"additional","affiliation":[{"name":"CHU de Qu\u00e9bec-Universit\u00e9 Laval Research Center, Population Health and Optimal Health Practice Research Unit (Trauma-Emergency-Critical Care Medicine), CHU de Qu\u00e9bec-Universit\u00e9 Laval, Qu\u00e9bec City, Qu\u00e9bec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomas H","family":"Torkomyan","sequence":"additional","affiliation":[{"name":"CHU de Qu\u00e9bec-Universit\u00e9 Laval Research Center, Population Health and Optimal Health Practice Research Unit (Trauma-Emergency-Critical Care Medicine), CHU de Qu\u00e9bec-Universit\u00e9 Laval, Qu\u00e9bec City, Qu\u00e9bec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine","family":"Ouellet","sequence":"additional","affiliation":[{"name":"CHU de Qu\u00e9bec-Universit\u00e9 Laval Research Center, Population Health and Optimal Health Practice Research Unit (Trauma-Emergency-Critical Care Medicine), CHU de Qu\u00e9bec-Universit\u00e9 Laval, Qu\u00e9bec City, Qu\u00e9bec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francois","family":"Lauzier","sequence":"additional","affiliation":[{"name":"CHU de Qu\u00e9bec-Universit\u00e9 Laval Research Center, Population Health and Optimal Health Practice Research Unit (Trauma-Emergency-Critical Care Medicine), CHU de Qu\u00e9bec-Universit\u00e9 Laval, Qu\u00e9bec City, Qu\u00e9bec, Canada"},{"name":"Department of Anesthesiology and Critical Care Medicine, Division of Critical Care Medicine, Universit\u00e9 Laval, Facult\u00e9 de M\u00e9decine, Qu\u00e9bec City, Qu\u00e9bec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shane","family":"English","sequence":"additional","affiliation":[{"name":"Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada"},{"name":"Division of Critical Care, Department of Medicine, University of Ottawa, Ottawa, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynne","family":"Moore","sequence":"additional","affiliation":[{"name":"CHU de Qu\u00e9bec-Universit\u00e9 Laval Research Center, Population Health and Optimal Health Practice Research Unit (Trauma-Emergency-Critical Care Medicine), CHU de Qu\u00e9bec-Universit\u00e9 Laval, Qu\u00e9bec City, Qu\u00e9bec, Canada"},{"name":"Department of Preventive and Social Medicine, Universite Laval, Faculte de M\u00e9decine, Qu\u00e9bec City, Qu\u00e9bec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5675-8791","authenticated-orcid":false,"given":"Alexis F","family":"Turgeon","sequence":"additional","affiliation":[{"name":"CHU de Qu\u00e9bec-Universit\u00e9 Laval Research Center, Population Health and Optimal Health Practice Research Unit (Trauma-Emergency-Critical Care Medicine), CHU de Qu\u00e9bec-Universit\u00e9 Laval, Qu\u00e9bec City, Qu\u00e9bec, Canada"},{"name":"Department of Anesthesiology and Critical Care Medicine, Division of Critical Care Medicine, Universit\u00e9 Laval, Facult\u00e9 de M\u00e9decine, Qu\u00e9bec City, Qu\u00e9bec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,3,19]]},"reference":[{"key":"2026031908351695000_16.3.e108337.1","doi-asserted-by":"publisher","DOI":"10.1016\/s1474-4422(22)00309-x"},{"key":"2026031908351695000_16.3.e108337.2","doi-asserted-by":"crossref","first-page":"564","DOI":"10.3171\/2009.12.JNS09689","article-title":"Role of extracellular glutamate measured by cerebral microdialysis in severe traumatic brain injury","volume":"113","author":"Chamoun","year":"2010","journal-title":"JNS"},{"key":"2026031908351695000_16.3.e108337.3","doi-asserted-by":"publisher","DOI":"10.1126\/science.2567056"},{"key":"2026031908351695000_16.3.e108337.4","doi-asserted-by":"publisher","DOI":"10.1016\/J.NEURON.2018.05.018"},{"key":"2026031908351695000_16.3.e108337.5","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.brainresbull.2011.05.004","article-title":"The role of glutamate receptors in traumatic brain injury: Implications for postsynaptic density in pathophysiology","volume":"85","author":"Luo","year":"2011","journal-title":"Brain Res Bull"},{"key":"2026031908351695000_16.3.e108337.6","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2014.116","article-title":"Postsynaptic scaffold protein Homer 1a protects against traumatic brain injury via regulating group I metabotropic glutamate receptors","volume":"5","author":"Luo","year":"2014","journal-title":"Cell Death Dis"},{"key":"2026031908351695000_16.3.e108337.7","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(02)00164-3"},{"key":"2026031908351695000_16.3.e108337.8","doi-asserted-by":"publisher","DOI":"10.1097\/00000542-199704000-00021"},{"key":"2026031908351695000_16.3.e108337.9","doi-asserted-by":"publisher","DOI":"10.1016\/0006-8993(94)90357-3"},{"key":"2026031908351695000_16.3.e108337.10","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1056\/NEJM198811033191813","article-title":"Therapeutic use of magnesium sulfate in selected cases of cerebral ischemia and seizure","volume":"319","author":"Goldman","year":"1988","journal-title":"N Engl J Med"},{"key":"2026031908351695000_16.3.e108337.11","doi-asserted-by":"publisher","DOI":"10.1097\/01.CCM.0000156293.35868.B2"},{"key":"2026031908351695000_16.3.e108337.12","doi-asserted-by":"crossref","unstructured":"Willis C , Lybrand S , Bellamy N , et al . Excitatory amino acid inhibitors for traumatic brain injury. Cochrane Database of Systematic Reviews 2003;2012. doi:10.1002\/14651858.CD003986.pub2","DOI":"10.1002\/14651858.CD003986.pub2"},{"key":"2026031908351695000_16.3.e108337.13","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1097\/SCS.0000000000001339","article-title":"Magnesium Sulfate for Acute Traumatic Brain Injury","volume":"26","author":"Li","year":"2015","journal-title":"J Craniofac Surg"},{"key":"2026031908351695000_16.3.e108337.14","article-title":"Magnesium for acute traumatic brain injury","volume":"8","author":"Arango","year":"2008","journal-title":"Cochrane Database Syst Rev"},{"key":"2026031908351695000_16.3.e108337.15","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1007\/s12028-024-02075-2","article-title":"Ketamine for Critically Ill Patients with Severe Acute Brain Injury: A Systematic Review with Meta-analysis and Trial Sequential Analysis of Randomized Clinical Trials","volume":"42","author":"Andreasen","year":"2025","journal-title":"Neurocrit Care"},{"key":"2026031908351695000_16.3.e108337.16","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1097\/TA.0000000000003363","article-title":"Assessment of the effect of amantadine in patients with traumatic brain injury: A meta-analysis","volume":"92","author":"Mohamed","year":"2022","journal-title":"J Trauma Acute Care Surg"},{"key":"2026031908351695000_16.3.e108337.17","doi-asserted-by":"crossref","first-page":"114436","DOI":"10.1016\/j.expneurol.2023.114436","article-title":"Esketamine is neuroprotective against traumatic brain injury through its modulation of autophagy and oxidative stress via AMPK\/mTOR-dependent TFEB nuclear translocation","volume":"366","author":"Tang","year":"2023","journal-title":"Exp Neurol"},{"key":"2026031908351695000_16.3.e108337.18","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s13054-020-03452-x","article-title":"Ketamine in acute phase of severe traumatic brain injury \u201can old drug for new uses?\u201d","volume":"25","author":"Godoy","year":"2021","journal-title":"Crit Care"},{"key":"2026031908351695000_16.3.e108337.19","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics14010152","article-title":"Revisiting Excitotoxicity in Traumatic Brain Injury: From Bench to Bedside","volume":"14","author":"Baracaldo-Santamar\u00eda","year":"2022","journal-title":"Pharmaceutics"},{"key":"2026031908351695000_16.3.e108337.20","doi-asserted-by":"crossref","unstructured":"Higgins JPT , Thomas J , Chandler J , et al . Cochrane handbook for systematic reviews of interventions. 1st edn. Wiley, 2019.","DOI":"10.1002\/9781119536604"},{"key":"2026031908351695000_16.3.e108337.21","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"2026031908351695000_16.3.e108337.22","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(74)91639-0"},{"key":"2026031908351695000_16.3.e108337.23","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.44.4.285"},{"key":"2026031908351695000_16.3.e108337.24","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(75)92830-5"},{"key":"2026031908351695000_16.3.e108337.25","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1102077"},{"key":"2026031908351695000_16.3.e108337.26","doi-asserted-by":"crossref","unstructured":"Cooper DJ , Nichol AD , Bailey M , et al . Effect of Early Sustained Prophylactic Hypothermia on Neurologic Outcomes Among Patients With Severe Traumatic Brain Injury: The POLAR Randomized Clinical Trial. JAMA 2018;320. doi:10.1001\/jama.2018.17075","DOI":"10.1001\/jama.2018.17075"},{"key":"2026031908351695000_16.3.e108337.27","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2016.01.021"},{"key":"2026031908351695000_16.3.e108337.28","unstructured":"Rohatgi A . WebPlotDigitizer. n.d. Available: https:\/\/automeris.io"},{"key":"2026031908351695000_16.3.e108337.29","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"2026031908351695000_16.3.e108337.30","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2288-5-13"},{"key":"2026031908351695000_16.3.e108337.31","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.327.7414.557"},{"key":"2026031908351695000_16.3.e108337.32","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.200077"},{"key":"2026031908351695000_16.3.e108337.33","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2010.04.026"},{"key":"2026031908351695000_16.3.e108337.34","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2007.03.013"},{"key":"2026031908351695000_16.3.e108337.35","doi-asserted-by":"crossref","DOI":"10.5005\/jaypee-journals-10071-24933.4","article-title":"A Prospective Randomised, Double-blinded Study on the Cerebral Haemodynamic Effects of Ketamine Versus Propofol Sedation in Patients with Severe Traumatic Brain Injury Admitted in Trauma Intensive Care","volume":"29","author":"Jain","year":"2025","journal-title":"Indian J Crit Care Med"},{"key":"2026031908351695000_16.3.e108337.36","first-page":"547","article-title":"Safety of extended administration to head injured patients of Aptiganel HCL (Cerestat), a non-competitive NMDA antagonist (abstract)","volume":"61","author":"Teasdale","year":"1996","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2026031908351695000_16.3.e108337.37","first-page":"468","article-title":"Experience with the competitive NMDA antagonist CGS19755 (Selfotel) in severe human head injury: A Phase II Study (abstract)","volume":"12","author":"Bullock","year":"1995","journal-title":"J Neurotrauma 3rd Int Neurotrauma Symp"},{"key":"2026031908351695000_16.3.e108337.38","first-page":"468","article-title":"The effect of early administration of magnesium on severe head injury: A pilot study (abstract)","volume":"12","author":"Palter","year":"1995","journal-title":"J Neurotrauma: 3rd Int Neurotrauma Symp"},{"key":"2026031908351695000_16.3.e108337.39","unstructured":"Cambridge NeuroScience Inc . Efficacy and safety of cerestat (aptiganel HCI) as a neuroprotective following severe traumatic brain injury. Protocol No CNS1102-012. 1995."},{"key":"2026031908351695000_16.3.e108337.40","unstructured":"Miller LP , Hayes RL , Newcomb JK . Chapter 20, Andrew Maas: clinical trials in head injury: Europe. In: Head Trauma: Basic, Preclinical, and Clinical Directions. Wiley-Liss, 2001."},{"key":"2026031908351695000_16.3.e108337.41","doi-asserted-by":"publisher","DOI":"10.1089\/neu.2006.0024"},{"key":"2026031908351695000_16.3.e108337.42","unstructured":"Synthelabo Recherche LERS . Double-blind, placebo-controlled study to assess the efficacy and safety of SL 82.0715-10 in the treatment of severe head injury. 1992."},{"key":"2026031908351695000_16.3.e108337.43","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(05)70253-2"},{"key":"2026031908351695000_16.3.e108337.44","doi-asserted-by":"publisher","DOI":"10.3171\/jns.1999.91.5.0737"},{"key":"2026031908351695000_16.3.e108337.45","doi-asserted-by":"publisher","DOI":"10.1089\/neu.2005.22.1428"},{"key":"2026031908351695000_16.3.e108337.46","unstructured":"NCT01333488. Mild hypothermia and supplemental magnesium sulfate infusion in severe traumatic brain injury (TBI) subjects. 2015. Available: https:\/\/clinicaltrials.gov\/study\/NCT01333488"},{"key":"2026031908351695000_16.3.e108337.47","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(06)70630-5"},{"key":"2026031908351695000_16.3.e108337.48","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S0028-3770(21)00116-8","article-title":"Neuroprotective effect of gacyclidine: A multicenter double-blind pilot trial in patients with acute traumatic brain injury","volume":"50","author":"Lepeintre","year":"2004","journal-title":"Neurochirurgie"},{"key":"2026031908351695000_16.3.e108337.49","doi-asserted-by":"publisher","DOI":"10.1097\/01.CCM.0000162491.26292.98"},{"key":"2026031908351695000_16.3.e108337.50","doi-asserted-by":"publisher","DOI":"10.1097\/01.CCM.0000044505.24727.16"},{"key":"2026031908351695000_16.3.e108337.51","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1007\/s13760-025-02803-1","article-title":"The effect of methylphenidate and amantadine co-administration on functional outcome of patients with blunt traumatic brain injury: A randomized controlled trial","volume":"125","author":"Farrokhi","year":"2025","journal-title":"Acta Neurol Belg"},{"key":"2026031908351695000_16.3.e108337.52","doi-asserted-by":"crossref","first-page":"598","DOI":"10.23736\/S0390-5616.21.05266-8","article-title":"A placebo-controlled randomized clinical trial of amantadine hydrochloride for evaluating the functional improvement of patients following severe acute traumatic brain injury","volume":"67","author":"Shimia","year":"2023","journal-title":"J Neurosurg Sci"},{"key":"2026031908351695000_16.3.e108337.53","doi-asserted-by":"crossref","first-page":"1179069518824851","DOI":"10.1177\/1179069518824851","article-title":"The Effect of Oral Administration of Amantadine on Neurological Outcome of Patients With Diffuse Axonal Injury in ICU","volume":"13","author":"Abbasivash","year":"2019","journal-title":"J Exp Neurosci"},{"key":"2026031908351695000_16.3.e108337.54","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1080\/02699052.2018.1476733","article-title":"The effects of amantadine on traumatic brain injury outcome: a double-blind, randomized, controlled, clinical trial","volume":"32","author":"Ghalaenovi","year":"2018","journal-title":"Brain Inj"},{"key":"2026031908351695000_16.3.e108337.55","doi-asserted-by":"crossref","unstructured":"Ramezani A , Ala S , Ehteshami S , et al . The Effects of Memantine on the Glasgow Coma Scale, Sequential Organ Failure Assessment Score, and Neuron-Specific Enolase Serum Levels in Traumatic Brain Injury Patients. J Nurs Midwifery Sci 2023;10. doi:10.5812\/jnms-132811","DOI":"10.5812\/jnms-132811"},{"key":"2026031908351695000_16.3.e108337.56","unstructured":"Salehpour F , Shakeri M , Ahmadvand A , et al . Magnesium Sulfate Effect on the Clinical Course and GCS of Patients with a Severe Diffuse Axonal Injury. Arch Adv Biosci 2012;3. doi:10.22037\/jps.v3i4.3502"},{"key":"2026031908351695000_16.3.e108337.57","first-page":"113","article-title":"Placebo-controlled trial of oral amantadine and zolpidem efficacy on the outcome of patients with acute severe traumatic brain injury and diffuse axonal injury","volume":"13","author":"Shafiee","year":"2022","journal-title":"Casp J Intern Med"},{"key":"2026031908351695000_16.3.e108337.58","unstructured":"He B , Zhang R , Li Q , et al . A study of the curative effect of magnesium sulfate in severe traumatic brain injury. Chinese J Crit Care Med 2011."},{"key":"2026031908351695000_16.3.e108337.59","unstructured":"Zhang S , Li J , Zhi D , et al . A study of the effect of extrinsic ionized magnesium treatment in the patients with severe traumatic brain injury. Chinese J Neurosurg 2006;76\u20138."},{"key":"2026031908351695000_16.3.e108337.60","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.2147\/TCRM.S109482","article-title":"The effects of magnesium sulfate therapy after severe diffuse axonal injury","volume":"12","author":"Zhao","year":"2016","journal-title":"Ther Clin Risk Manag"},{"key":"2026031908351695000_16.3.e108337.61","doi-asserted-by":"publisher","DOI":"10.1016\/S0973-0508(08)80025-1"},{"key":"2026031908351695000_16.3.e108337.62","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s12028-025-02274-5","article-title":"Effect of Ketamine Analgosedation on Neurological Outcome in patients with Severe Traumatic Brain Injury: A Randomized Controlled Pilot Study","volume":"44","author":"Burman","year":"2026","journal-title":"Neurocrit Care"},{"key":"2026031908351695000_16.3.e108337.63","doi-asserted-by":"crossref","unstructured":"Badre D , Elbeialy MAK , Fathy M . Citicoline-Amantadine Trial in Traumatic Brain Injury: A Prospective Randomized Study. J Neurotrauma 2025;08977151251375914. doi:10.1177\/08977151251375914","DOI":"10.1177\/08977151251375914"},{"key":"2026031908351695000_16.3.e108337.64","first-page":"907","article-title":"Magnesium Sulphateas Neuroprotective in Post Traumatic Brain Injury","volume":"92","author":"Abdelwahab","year":"2024","journal-title":"Med J Cairo Univ"},{"key":"2026031908351695000_16.3.e108337.65","doi-asserted-by":"publisher","DOI":"10.1097\/00003246-200203000-00009"},{"key":"2026031908351695000_16.3.e108337.66","doi-asserted-by":"publisher","DOI":"10.1097\/00005650-199206000-00002"},{"key":"2026031908351695000_16.3.e108337.67","doi-asserted-by":"publisher","DOI":"10.1097\/CCM.0b013e318228236f"},{"key":"2026031908351695000_16.3.e108337.68","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.annemergmed.2014.06.018","article-title":"The effect of ketamine on intracranial and cerebral perfusion pressure and health outcomes: a systematic review","volume":"65","author":"Cohen","year":"2015","journal-title":"Ann Emerg Med"},{"key":"2026031908351695000_16.3.e108337.69","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1080\/02699052.2019.1631482","article-title":"Efficacy of amantadine on behavioural problems due to acquired brain injury: A systematic review","volume":"33","author":"Ter Mors","year":"2019","journal-title":"Brain Inj"},{"key":"2026031908351695000_16.3.e108337.70","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1080\/02699052.2022.2109749","article-title":"N-methyl-D-aspartate receptor antagonists in improving cognitive deficits following traumatic brain injury: a systematic review","volume":"36","author":"Khormali","year":"2022","journal-title":"Brain Inj"},{"key":"2026031908351695000_16.3.e108337.71","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.seizure.2022.09.020","article-title":"Efficacy and safety of perampanel in epilepsy: A systematic review and meta-analysis of randomised controlled trials","volume":"102","author":"Lavu","year":"2022","journal-title":"Seizure"},{"key":"2026031908351695000_16.3.e108337.72","doi-asserted-by":"crossref","unstructured":"Zhang Z , Gao X , Tian Z , et al . Preso enhances mGluR1-mediated excitotoxicity by modulating the phosphorylation of mGluR1-Homer1 complex and facilitating an ER stress after traumatic brain injury. Cell Death Discov 2024;10. doi:10.1038\/s41420-024-01916-5","DOI":"10.1038\/s41420-024-01916-5"},{"key":"2026031908351695000_16.3.e108337.73","doi-asserted-by":"crossref","first-page":"113222","DOI":"10.1016\/j.expneurol.2020.113222","article-title":"Acute administration of perampanel, an AMPA receptor antagonist, reduces cognitive impairments after traumatic brain injury in rats","volume":"327","author":"Aida","year":"2020","journal-title":"Exp Neurol"},{"key":"2026031908351695000_16.3.e108337.74","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1161\/STROKEAHA.118.021916","article-title":"Intravenous Magnesium Sulfate in Acute Stroke: A Systematic Review and Meta-Analysis of Randomized Controlled Trials","volume":"50","author":"Avgerinos","year":"2019","journal-title":"Stroke"},{"key":"2026031908351695000_16.3.e108337.75","article-title":"Excitatory amino acid antagonists for acute stroke","volume":"2003","author":"Muir","year":"2003","journal-title":"Cochrane Database Syst Rev"},{"key":"2026031908351695000_16.3.e108337.76","doi-asserted-by":"crossref","first-page":"730","DOI":"10.3109\/02699051003610516","article-title":"Magnesium sulphate in the management of patients with aneurysmal subarachnoid haemorrhage: a meta-analysis of prospective controlled trials","volume":"24","author":"Ma","year":"2010","journal-title":"Brain Inj"},{"key":"2026031908351695000_16.3.e108337.77","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.115.010575"},{"key":"2026031908351695000_16.3.e108337.78","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.jcrc.2012.07.001","article-title":"Prophylactic magnesium for improving neurologic outcome after aneurysmal subarachnoid hemorrhage: Systematic review and meta-analysis","volume":"28","author":"Golan","year":"2013","journal-title":"J Crit Care"},{"key":"2026031908351695000_16.3.e108337.79","doi-asserted-by":"crossref","DOI":"10.1186\/cc10017","article-title":"Intravenous magnesium sulphate for aneurysmal subarachnoid hemorrhage: an updated systemic review and meta-analysis","volume":"15","author":"Wong","year":"2011","journal-title":"Crit Care"},{"key":"2026031908351695000_16.3.e108337.80","doi-asserted-by":"publisher","DOI":"10.1089\/neu.2015.4226"},{"key":"2026031908351695000_16.3.e108337.81","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(11)70243-5"},{"key":"2026031908351695000_16.3.e108337.82","doi-asserted-by":"publisher","DOI":"10.3171\/2017.12.JNS171665"},{"key":"2026031908351695000_16.3.e108337.83","article-title":"Ketamine suppresses spreading depolarizations in a case of severe brain trauma","volume":"29","author":"Hartings","year":"2018","journal-title":"Neurocrit Care"},{"key":"2026031908351695000_16.3.e108337.84","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adj2417","article-title":"Memantine inhibits cortical spreading depolarization and improves neurovascular function following repetitive traumatic brain injury","volume":"9","author":"MacLean","year":"2023","journal-title":"Sci Adv"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2025-108337","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T15:35:31Z","timestamp":1773934531000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2025-108337"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":84,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,3,19]]},"published-print":{"date-parts":[[2026,3]]}},"alternative-id":["10.1136\/bmjopen-2025-108337"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2025-108337","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3]]}}}